For foreign counsel handling pharmaceutical or agrochemical patents in Japan, Patent Term Extension (PTE) can extend the effective patent life by up to 5 years — often the difference between a commercially viable product launch and a generic-eroded portfolio. This guide covers PTE eligibility, calculation, and the 3-month filing deadline that catches many foreign filers off guard.
Table of Contents
Japan Patent Term Extension is governed by Articles 67-2 through 67-9 of the Patent Act. The system was introduced in 1988 to harmonize with US PTE (35 U.S.C. § 156) and EU SPC (Supplementary Protection Certificate). However, the Japanese system has unique features that differ from both.
5-Year Maximum: PTE extends the patent term by up to 5 years, capped at the actual non-working period due to regulatory review. The total extended term cannot exceed the original term + 5 years.
Four conditions must be met:
The PTE term equals the regulatory non-working period, calculated as:
Formula: PTE Term = Approval Date − max(Patent Grant Date, Clinical Trial Start Date) − Applicant's Delay Days
Practical examples:
| Scenario | Patent Grant | Trial Start | Approval | PTE Term |
|---|---|---|---|---|
| Pharma A | 2015-06-01 | 2016-09-15 | 2024-04-01 | 5 years (max) |
| Pharma B | 2020-01-10 | 2019-12-01 | 2024-02-15 | 4 years 1 month |
| Agrochem C | 2018-03-20 | 2020-05-10 | 2023-08-01 | 3 years 2 months |
Critical Supreme Court precedent (Pacif Capsule case, 2017) clarified the PTE scope. The extended right covers:
Multiple PTE Strategy: If your patent supports multiple products (e.g., different dosage strengths, different indications approved at different times), file separate PTE applications for each. This maximizes coverage but requires precise tracking.
PTE-extended patents are heavily attacked by generic challengers. Defensive strategy:
Need Japan IP Support?
Quote within 24 hours · English/Chinese/Korean/German/French/Spanish/Portuguese
Request a QuoteService OverviewQ. What is Japan Patent Term Extension (PTE)?
A. PTE (特許権の存続期間の延長) compensates for regulatory delays. If a patented pharmaceutical or agrochemical product cannot be commercially worked due to MHLW (PMDA) or MAFF approval requirements, the patent term can be extended up to 5 years beyond the standard 20-year term.
Q. Which patents are eligible for PTE in Japan?
A. Patents covering: (1) pharmaceutical products requiring approval under the Pharmaceutical Affairs Act, (2) agrochemicals requiring approval under the Agricultural Chemicals Regulation Act. Medical devices and biologics requiring regulatory approval are also eligible.
Q. How is the PTE term calculated?
A. The PTE equals the period the patent could not be worked due to regulatory disposition, capped at 5 years. The "non-working period" starts from the later of patent grant date or clinical trial start, and ends on the date of MHLW marketing approval.
Q. When must I file the PTE application?
A. Within 3 months of the regulatory approval (MHLW marketing authorization). Late filing cannot be remedied. Missing this deadline means losing the entire PTE benefit.
Q. Does PTE cover multiple products?
A. One patent can support multiple PTE applications if multiple products are approved. Each product requires a separate PTE filing with the corresponding approval data. This is critical for platform patents covering multiple commercial products.